ASP 7147

Drug Profile

ASP 7147

Alternative Names: ASP7147

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Seldar Pharma
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Bombesin BB2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome

Most Recent Events

  • 13 Apr 2016 Phase-II development for Irritable bowel syndrome is ongoing in USA
  • 01 Jul 2014 Seldar Pharma completes a phase II trial in Irritable bowel syndrome in USA (NCT01896583)
  • 26 Nov 2013 Phase-II clinical trials in Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top